Where do Oryzon Genomics shares trade and what are the company's identifying codes?

The source identifies Oryzon Genomics by ISIN Code ES0167733015 and the ticker symbol ORY. It does not identify a trading venue.

How many Oryzon Genomics voting rights were represented at the Extraordinary General Shareholders' Meeting?

A total of 33,581,589 Oryzon Genomics voting rights were represented at the meeting, either in person or by proxy. This represented 37.7938% of the company's share capital.

What voting results did Oryzon Genomics report for the resolutions?

Oryzon Genomics said shareholders approved all the proposed resolutions, with favourable votes ranging from 93% to 98%. The company said the results were based on voting at the Extraordinary General Shareholders' Meeting.

What change to its corporate purpose did Oryzon Genomics shareholders approve?

Shareholders approved a technical amendment to Article 2 of Oryzon Genomics' bylaws concerning the corporate purpose. The amendment is intended to adapt it to the New National Classification of Economic Activities, CNAE 2025.

What did Oryzon Genomics shareholders approve regarding board remuneration?

Shareholders approved an amendment to Article 11 of Oryzon Genomics' bylaws concerning remuneration of the Board of Directors. They also approved a new remuneration policy for directors.

How long will Oryzon Genomics' new director remuneration policy apply?

The new remuneration policy for directors applies from the date of its approval and for the following three financial years. The company specifies that these are the 2026, 2027, and 2028 financial years.

What long-term incentive plan did Oryzon Genomics shareholders approve?

Shareholders approved a 2026-2028 Long-Term Incentive Plan for executives and key personnel, including the Executive Chairman. The source does not provide further terms of the plan.

What share-based remuneration was approved for Oryzon Genomics' independent directors?

Shareholders approved fixed long-term share-based remuneration for Oryzon Genomics' independent directors. The company said this was intended to attract talent and reward the directors' dedication.

What capital increase did Oryzon Genomics shareholders approve?

Shareholders approved a capital increase through cash contributions, with the exclusion of pre-emptive subscription rights, for an effective amount of up to €125 million. They also delegated to the Board of Directors the power to set the date, the issue price or the procedure for determining it, and other issue conditions in accordance with Article 505 of the Spanish Companies Act.

What authority was delegated to the Oryzon Genomics Board of Directors?

The Board of Directors received delegated powers for the formalisation, correction, registration, interpretation, development and execution of the resolutions adopted by the General Shareholders' Meeting.

Where can investors find the full Oryzon Genomics voting results and approved resolutions?

Oryzon Genomics said the complete details of the approved resolutions and the voting results by separate item are available on the company's website.

What does Oryzon Genomics do according to the announcement?

Oryzon Genomics describes itself as a clinical-stage biopharmaceutical company and global leader in epigenetics. The announcement does not provide further detail about its operations.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon shareholders approve resolutions at December 2025 extraordinary meeting

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon shareholders approve resolutions at December 2025 extraordinary meeting

Published Monday, 15 December 2025

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Corporate update
Published: Monday, 15 December 2025
Source announcement: oryzon.com

Key figures
Measure	Figure
Favorable votes	93% to 98%
Capital increase	up to €125 million

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

Oryzon Genomics S.A. (ORY) announced shareholders approved all resolutions at its Extraordinary General Shareholders’ Meeting.

33,581,589 voting rights, representing 37.7938% of share capital, were represented at the meeting held last Friday in Madrid.
Shareholders approved all Board-proposed resolutions, with favorable votes ranging from 93% to 98%.
Approved Bylaws changes cover the corporate purpose and Board remuneration, including CNAE 2025 adaptation.
The new director Remuneration Policy applies from approval through 2026, 2027, and 2028; incentives and fixed share remuneration were also approved.
A 2026-2028 Long-Term Incentive Plan covers executives and key personnel, including the Executive Chairman; independent directors receive fixed long-term share remuneration.
A capital increase with an effective amount up to €125 million will use cash contributions and exclude preemptive subscription rights; the Board received authority over issue terms.

The Board also received powers to formalize, correct, register, interpret, develop, and execute the resolutions. The complete resolutions and separate-item vote results are available on the Company’s website.

Investor FAQs

Oryzon Genomics announced the voting results on December 15th, 2025. The Extraordinary General Shareholders' Meeting was held last Friday in Madrid, according to the company.

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON announces the voting results of December 2025 Extraordinary General Shareholders' Meeting
Published: Monday, 15 December 2025
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…